Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma

(2016) Daniel J. Royston et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Myeloma minimal residual disease testing in the United States: Evidence of improved standardization

(2016) Dalia Salem et al.   AMERICAN JOURNAL OF HEMATOLOGY

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

(2016) B. Paiva et al.   BLOOD

High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes

(2016) Yinlei Bai et al.   Journal of Hematology & Oncology

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Multiple Myeloma: Diagnosis and Treatment

(2016) S. Vincent Rajkumar et al.   MAYO CLINIC PROCEEDINGS

Promising therapies in multiple myeloma

(2015) G. Bianchi et al.   BLOOD

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

(2015) J. J. M. van Dongen et al.   BLOOD

New criteria for response assessment: role of minimal residual disease in multiple myeloma

(2015) B. Paiva et al.   BLOOD

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

(2015) A. C. Rawstron et al.   BLOOD

Treatment for patients with newly diagnosed multiple myeloma in 2015

(2015) María-Victoria Mateos et al.   BLOOD REVIEWS

Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?

(2015) B. Paiva et al.   CLINICAL CANCER RESEARCH

Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases

(2015) Fanny Pojero et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service

(2015) Andy C. Rawstron et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting

(2015) Maria Arroz et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Assessment of minimal residual disease in myeloma and the need for a consensus approach

(2015) Andy C. Rawstron et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry

(2015) Brent L. Wood   CYTOMETRY PART B-CLINICAL CYTOMETRY

Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition

(2015) Maryalice Stetler-Stevenson et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma

(2015) Juan Flores-Montero et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Multiple myeloma

(2015) Christoph Röllig et al.   LANCET

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives

(2015) S Lonial et al.   LEUKEMIA

Minimal residual disease in multiple myeloma: bringing the bench to the bedside

(2015) Sham Mailankody et al.   Nature Reviews Clinical Oncology

Deep Response in Multiple Myeloma: A Critical Review

(2015) Mariateresa Fulciniti et al.   Biomed Research International

Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma

(2014) B. Paiva et al.   BLOOD

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

(2014) J. Martinez-Lopez et al.   BLOOD

Curing myeloma at last: defining criteria and providing the evidence

(2014) B. Barlogie et al.   BLOOD

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival

(2014) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma

(2014) R Silvennoinen et al.   Blood Cancer Journal

Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity

(2013) A. Flanders et al.   BLOOD

Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study

(2013) Joaquin Martinez-Lopez et al.   BRITISH JOURNAL OF HAEMATOLOGY

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

(2013) Andy C. Rawstron et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials

(2013) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

(2013) N Puig et al.   LEUKEMIA

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

(2013) E M Ocio et al.   LEUKEMIA

Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders

(2013) M Ladetto et al.   LEUKEMIA

Association of response endpoints with survival outcomes in multiple myeloma

(2013) S Lonial et al.   LEUKEMIA

Overview of clinical flow cytometry data analysis: recent advances and future challenges

(2013) Carlos E. Pedreira et al.   TRENDS IN BIOTECHNOLOGY

Initial treatment of transplant-ineligible patients in multiple myeloma

(2013) María-Victoria Mateos et al.   Expert Review of Hematology

A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma

(2013) N Robillard et al.   Blood Cancer Journal

Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma

(2012) Noemí Puig et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

(2012) T Kalina et al.   LEUKEMIA

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

(2012) S Z Usmani et al.   LEUKEMIA

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

(2012) J J M van Dongen et al.   LEUKEMIA

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

(2011) B. Paiva et al.   BLOOD

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

(2011) F. Gay et al.   BLOOD

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

(2011) Bruno Paiva et al.   JOURNAL OF CLINICAL ONCOLOGY

Generation of flow cytometry data files with a potentially infinite number of dimensions

(2008) Carlos E. Pedreira et al.   CYTOMETRY PART A

A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders

(2008) C.E. Pedreira et al.   CYTOMETRY PART A

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

(2008) A. C. Rawstron et al.   HAEMATOLOGICA

Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

(2008) Juan José Lahuerta et al.   JOURNAL OF CLINICAL ONCOLOGY